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Background
Certain infections occur more frequently in HIV-infected
patients some of which are classified as AIDS-defining
events. Theoretical concerns have been raised that CCR5
antagonists may have an adverse effect on the immune
system. A 4-week immunotoxicology study in
cynomolgous monkeys did not demonstrate any adverse
effects of MVC on the immune system. MOTIVATE 1 and
MOTIVATE 2 are randomized, double-blind, placebo
(PBO)-controlled, Phase III studies assessing the safety
and efficacy of MVC in TE patients with CCR5-tropic HIV-
1. In both studies, MVC+OBT demonstrated significantly
greater virologic and immunologic efficacy and a similar
safety profile compared with PBO+OBT at 48 weeks.
Methods
Patients were randomized 2:2:1 to MVC QD (N = 414),
MVC BID (N = 426), or PBO (N = 209) + OBT. For this
analysis, data from both MVC arms were pooled (N =
840) and infections present at Day 1 were excluded. We
present the incidence of infections during the first 48
weeks of treatment for patients who received MVC and
PBO, in addition to exposure-adjusted incidence rates,
risk ratios and 95% CI.
Summary of results
840 patients received MVC and 209 received PBO. Mean
baseline CD4 (cells/μL) and viral load (VL, log10 copies/
mL), respectively, were 193 and 4.9 for MVC recipients
and 186 and 4.9 for PBO recipients. The unadjusted and
exposure-adjusted incidence of infections, including Cat-
egory C infections and exposure-adjusted risk ratio, is pre-
sented. (Table 1.)
Median baseline CD4 (cells/μL)and VL (log10 copies/mL)
for patients who did and did not develop sentinel or Cat-
egory C infections were 122 and 176 and 5.1 and 4.8 for
MVC recipients and 99 and 188 and 5.2 and 4.8 for PBO
recipients. Patients reporting infections had more previ-
ous Category C events and PBO recipients had shorter
median time to the onset of infections compared with
MVC recipients (0.42 years vs. 1.02 years; p < 0.0001).
Conclusion
To date, clinical data do not indicate that MVC is associ-
ated with clinically relevant increased rates of infections.
Data from Phase III TE studies do not indicate a difference
in the spectrum or severity of infections reported among
patients receiving MVC and those receiving PBO, except a
slightly increased rate of URTI and lower rate of pneumo-
nia on MVC vs. PBO. Longer duration of MVC therapy (48
vs. 24 weeks) did not show any effect on the incidence of
infections and no significant difference in the time of
onset of these events was seen.
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MVC (QD+BID) [N = 840]: 
exposure adjusted incidence*, 
unadjusted incidence (%)
Placebo [N = 209]: exposure 
adjusted incidence*, 
unadjusted incidence (%)
Risk Ratio (exposure 
adjusted): MVC/PBO (95% CI)
Infections and infestations among 
sentinel infections/Category C 
illnesses
27.04, 159 (18.93) 31.37, 33 (15.79) 0.86 (0.59, 1.25)
Selected Category C infections
Herpes simplex 4, 24 (2.86) 1.8, 2 (0.96) 2.22 (0.53, 9.40)
Oesophageal Candidiasis 2.5, 15 (1.79) 1.8, 2 (0.96) 1.39 (0.32, 6.07)
Oral Candidiasis 4.7, 28 (3.33) 7.4, 8 (3.83) 0.64 (0.29, 1.39)
Infections and infestations among 
adverse events
92.80, 447 (53.21) 132.90, 84 (40.19) 0.70 (0.55, 0.88)
Infections AEs of interest
Nasopharyngitis 11.3, 67 (7.98) 10.4, 11 (5.26) 1.09 (0.57, 2.06)
Pneumonia 3.1, 19 (2.26) 7.4, 8 (3.83) 0.42 (0.18, 0.96)
Upper RTI 16.1, 94 (11.2) 11.6, 12 (5.74) 1.39 (0.76, 2.53)
Meningitis viral 0.4, 2 (0.2) 0, 0 (0) ND**
*Adjusted to 100 years of subject exposure;** ND = not defined.Page 2 of 2
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